神经元核内包涵体病患者的脑脊液P-Tau181及其他生物标志物
这项回顾性观察研究比较了12例神经元核内包涵体病(NIID)患者与120例经脑脊液生物标志物确认的阿尔茨海默临床综合征患者及71例其他神经认知障碍患者的脑脊液生物标志物。NIID患者脑脊液p-tau181显著高于路易体痴呆、进行性核上性麻痹和皮质基底节综合征,与阿尔茨海默病相当;12例中11例(91.7%)高于50.0 pg/mL截断值,且多数Aβ42正常。
要点
- NIID患者脑脊液p-tau181为72.7 ± 24.8 pg/mL,12例中11例(91.7%)高于50.0 pg/mL截断值。
- NIID中p-tau181升高而Aβ42正常(A-T+)的比例为75%,显著高于路易体痴呆、进行性核上性麻痹和皮质基底节综合征。
- NIID患者脑脊液HVA和5-HIAA浓度显著高于疾病对照。
核心结论
- NIID患者脑脊液p-tau181升高且无淀粉样蛋白沉积,提示NIID中tau磷酸化或p-tau分泌的分子机制可能发生改变。
研究设计与样本
- 回顾性观察研究,比较12例NIID患者、120例经脑脊液生物标志物生物学确认的阿尔茨海默临床综合征患者及71例临床诊断为其他神经认知障碍的患者(路易体痴呆24例、额颞叶痴呆13例、进行性核上性麻痹21例、皮质基底节综合征13例)。
- 对6例NIID患者进行了匹兹堡化合物B(PiB)淀粉样PET检查。
主要发现
- NIID患者脑脊液p-tau181为72.7 ± 24.8 pg/mL,显著高于路易体痴呆、进行性核上性麻痹和皮质基底节综合征,与阿尔茨海默病相当。
- 12例NIID患者中11例(91.7%)脑脊液p-tau181高于50.0 pg/mL截断值。
- 上述11例中仅2例脑脊液Aβ42降低,这2例PiB PET分别显示阴性或轻度局部聚集;其余4例接受PiB PET检查者均为阴性。
- NIID中p-tau181升高而Aβ42正常(A-T+)的比例为75%,显著高于路易体痴呆(4.2%)、进行性核上性麻痹(4.8%)和皮质基底节综合征(7.7%)。
- NIID患者脑脊液HVA和5-HIAA浓度显著高于疾病对照。
关键数值与推荐
- 脑脊液p-tau181截断值为50.0 pg/mL。
- NIID患者平均年龄71.3岁,阿尔茨海默病74.6岁,路易体痴呆76.8岁,额颞叶痴呆70.2岁,进行性核上性麻痹75.5岁,皮质基底节综合征71.9岁。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: CSF tau phosphorylated at threonine 181 (p-tau181) is a widely used biomarker for Alzheimer disease (AD) and has recently been regarded to reflect β-amyloid and/or p-tau deposition in the AD brain. Neuronal intranuclear inclusion disease (NIID) is a neurodegenerative disease characterized by intranuclear inclusions in neurons, glial cells, and other somatic cells. Symptoms include dementia, neuropathy, and others. CSF biomarkers were not reported. The objective of this study was to investigate whether CSF biomarkers including p-tau181 are altered in patients with NIID. METHODS: This was a retrospective observational study. CSF concentrations of p-tau181, total tau, amyloid-beta 1-42 (Aβ42), monoamine metabolites homovanillic acid (HVA), and 5-hydroxyindole acetic acid (5-HIAA) were compared between 12 patients with NIID, 120 patients with Alzheimer clinical syndrome biologically confirmed based on CSF biomarker profiles, and patients clinically diagnosed with other neurocognitive disorders (dementia with Lewy bodies [DLB], 24; frontotemporal dementia [FTD], 13; progressive supranuclear palsy [PSP], 21; and corticobasal syndrome [CBS], 13). Amyloid PET using Pittsburgh compound B (PiB) was performed in 6 patients with NIID. RESULTS: The mean age of patients with NIID, AD, DLB, FTD, PSP, and CBS was 71.3, 74.6, 76.8, 70.2, 75.5, and 71.9 years, respectively. CSF p-tau181 was significantly higher in NIID (72.7 ± 24.8 pg/mL) compared with DLB, PSP, and CBS and was comparable between NIID and AD. CSF p-tau181 was above the cutoff value (50.0 pg/mL) in 11 of 12 patients with NIID (91.7%). Within these patients, only 2 patients showed decreased CSF Aβ42, and these patients showed negative or mild local accumulation in PiB PET, respectively. PiB PET scans were negative in the remaining 4 patients tested. The proportion of patients with increased CSF p-tau181 and normal Aβ42 (A-T+) was significantly higher in NIID (75%) compared with DLB, PSP, and CBS (4.2%, 4.8%, and 7.7%, respectively). CSF HVA and 5-HIAA concentrations were significantly higher in patients with NIID compared with disease controls. DISCUSSION: CSF p-tau181 was increased in patients with NIID without amyloid accumulation. Although the deposition of p-tau has not been reported in NIID brains, the molecular mechanism of tau phosphorylation or secretion of p-tau may be altered in NIID.
引用
- Kurihara M, Komatsu H, Sengoku R, et al. CSF P-Tau181 and Other Biomarkers in Patients With Neuronal Intranuclear Inclusion Disease. Neurology. 2022. PMID: 36517236. doi:10.1212/WNL.0000000000201647
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。